

TOTAL 2022

6 387 000 kr

DIARIE-NR	SÖKANDES NAMN	PROJEKT
FB22-01	ÖSTERLUND Tobias	Identification and monitoring of patient-specific mutations in sarcomas using sequencing
FB22-02	CRESCITELLI Rossella	Analysis of DNA-derived extracellular vesicles from melanoma patients: new marker in monitoring melanoma disease and treatment progression
FB22-03	RUIZ M. Santiago	Patient-derived scaffold cultures including cancer-associated fibroblasts - An in vivo mimicking model system for drug discovery
FB22-04	MELGUIZO S. Dario	Improved mechanistic understanding of doxorubicin-induced cardiac toxicity in cancer treatment
FB22-05	LINDÉN Malin	FET fusion oncogenes in human sarcomas-Molecular characterization of oncoproteins, binding partners and epigenetic effects
FB22-06	AXELSSON (fd.KARLSSON) Therese	Hälsorelaterad livskvalitet (HRQL) hos larynxcancerpatienter - en randomiserad interventionsstudie med logopedisk röstrehabilitering
FB22-07	ROHLIN Anna	Identification of genetic biomarkers in lungcancer tumors to predict resistance or response to immunotherapy
FB22-08	EKHOLM Maria	Personalised Disease Monitoring for Patients with Breast Cancer with focus on ctDNA and Immun cell profiling
FB22-09	GUSTAFSSON Anna	Tumour microenvironment and breast cancer stem cell propagation
FB22-10	WARAKY Ahmed	Development of pre-clinical therapy model for patients with pediatric(7;12) AML
FB22-11	BJURSTEN Sara	Mechanisms for exceptional response to immunotherapy in metastatic melanoma
FB22-12	ANDERSSON Lisa	Targeting FET fusion oncogenedriven regulation in sarcomas
FB22-13	JONASSON Emma	Profiling cellular heterogeneity in FET sarcomas using single-cell analysis
FB22-14	FILGES Stefan	Ultrasensitive mutation detection in melanoma from liquid biopsies
FB22-15	MICALLEF Peter	Two-tailed PCR for detection of fusion oncogenes in fluid samples in sarcoma
FB22-16	LYCKE Maria	Molecular biomarkers associated with lymph node metastases and recurrent low-risk endometrioid endometrial cancer
FB22-17	JAAKO Pekka	mRNA translation as a target in acute myeloid leukemia
FB22-19	BERG Tove	Hjärtsjukdom efter cancerbehandling i barndomen - ett epidemiologiskt populationsbaserat projekt
FB22-20	KARLSSON Ida	High-throughput Drug Screening for Cancer Stemcells of Pediatric High-Grade Gliomas
FB22-21	KEANE Simon	Fusion genes in pediatric glioma - Functionalstudies for precision medicine
FB22-22	EKSTRÖM Karin	Extracellular vesicles from breast cancer patients - the use as biomarkers for early detection and monitoring the disease
FB22-23	AL-AWAR Amin	Combination therapy of radionuclides and radiosensitizing for improved treatment of neuroendocrine tumors
FB22-24	SIAW Joachim T.	Mining MYC gene signatures to identify new targetable molecular vulnerabilities in high-risk neuroblastoma
FB22-25	DELAND Lily	Molecular genetics of paediatric brain tumours - relevance in clinical diagnostics and therapeutics
FB22-26	RANJI Parmida	Defining myxoid liposarkoma cell heterogeneity using in vivo-like patient-derived scaffold system
FB22-27	CORDOBA B. Carmen M.	The roll of the molecular chaperone CCT in cancer cell biology
FB22-28	ALFONZO Emilia	Sociodemographic status and gynecologic cancer - is survival and choice of treatment affected?...
FB22-29	JALNEFJORD Oscar	Noninvasive characterization of microvasculature in tumors
FB22-30	FEHR André	Genomic profiling of pleomorphic adenoma and carcinoma-ex-pleomorphic-adenoma of the salivary glands
FB22-31	BAKR Hana	Radionuclide therapy of SSTR expressing tumors

FB22-32	KRISTENSON Linnea	A CRISP approach to identify structures involved in NK cell targeting of leukemic cells
FB22-33	HUSSEIN Brwa A.	Antisense oligonucleotide therapeutics in Epstein-Barr virus-associated cancer
FB22-34	WIEL Clotilde	Identifying redox-dependent drivers and vulnerabilities of lung cancer metastasis
FB22-35	TÖRNELL Andreas	Antibodies and T-cell memory responses to COVID-19 vaccines after allogenic stem cell transplantation in patients with hematological cancer
FB22-36	MAGNUSSON Rasmus	A deep encoding of the human interactome for extracting cross-omic functional cancer-modules
FB22-37	ANDERSSON Mattias	Funktionella Studier av onkogenen MYB i adenoid cystisk cancer och cylindrom
FB22-38	GRAUERS WIKTORIN Hanna	Targeting surgery-induced inflammation in pancreas cancer
FB22-39	LUNA M. Manuel	Ultrasensitive short nucleid acids analysis in liquid biopsies
FB22-40	ANDERSSON Daniel	Ultrasensitive molecular analysis of plasma from FET sarcoma patients
FB22-41	NOWAK Iwona	Engaging nuclear RNA interference for targeting cancer cell growth
FB22-42	JÄWERT Fredrik	Kan analyser av genkopieförändringar i orala precanceroser prediktera cancerutveckling
FB22-43	PETERSSON Kerstin	Strålinducerad dysfagi hos patient med huvud-halscancer - identifiering av riskstrukturer och behandling av sväljningssvårigheter
FB22-44	HOLMQVIST Isak	Development of an ex vivo assay in antiviral drug testing: incorporation of patient-derived cells in tumor virus research
FB22-45	FÄLDT BEDING, Anna	The clinical importance of surviving in cancer
FB22-46	GUL Nadia	CRISPR/Cas9 genome wide screening approach to find novel drug sensitivity and resistance mechanisms in lung cancer
FB22-47	IRESIÖ Britt-Marie	Proteinsyntes i skelettmuskulatur vid progredierande cancersjukdom.
FB22-48	FOLKESSON Evelina	Functional authentication and enrichment of patient-derived tumour organoids for further use in clinical decision support
FB22-49	HOLDFELDT André	Neutrophils influence of the tumor microenvironment and breast cancer stem cell propagation
FB22-50	WÖHR Anne	Serine protease-mediated regulation of inflammation
FB22-51	MOLINARO Angela	Role of CA10 and CA11 in glioma growth
FB22-52	KAYA Mustafa	The role of inflammation in regulation of epithelial-mesenchymal transition (EMT) in the tumor microenvironment
FB22-53	VANNAS Christoffer	Therapeutic implication of targeting epigenetic signalling in FET oncogene sarcomas
FB22-54	XIE Guojiang	Single-cell drug screening for cancers caused by Epstein-Barr virus (?)
FB22-55	LINDHOLM Heléne	Metabolomic and immunologic profiling in Pancreatic cancer cell lines, basal levels and after digitoxin treatment
FB22-56	TIAN Yarong	Role of long non-coding RNA RPMS1 in Epstein-Barr virus malignancies
FB22-57	BADAMI Chiara	The role of BAP1 in NK cell targeting of uveal melanoma and K%&" cells
FB22-58	ISSDISAI Nuttida	Histamine induces myeloid cell production of the anti-metastatic protein thrombospondin-1
FB22-59	RUGWIZANGOGA Belson	Aspects of infection and development of lymphoma in Rwanda
FB22-60	PODRAZA-F. Agnieszka	Study of ASNA-1 and ENPL-1 interaction in relation to chemotherapy resistance
FB22-63	KAIDI Donia	Molekylär diagnostiskt test för säkrare stadiindelning av tidig koloncancer
FB22-64	SANDBERG Sofia	Bowel dysfunction after colon cancer surgery, a prospective multicenter study
FB22-65	GARRE Elena	Targeting the tumor microenvironment and tumor-associated macrophages for a precision medicine and diagnostics in breast cancer
FB22-66	BERNSON Elin	NK cellregulation in ovarian cancer - a potential immunotherapeutic target?

FB22-67	LINDER Anna	Early detection of gynecological cancer with a liquid biopsy approach - development of a screening tool
FB22-68	LARSSON Peter	Proteasome Inhibitors: New treatment Alternatives for triple-Negative Breast Cancer Subtypes
FB22-69	ALKAN KÄLLGREN Aylin	Prediction of treatment response in patients with rectal cancer by tumor infiltrating macrophages
FB22-70	CAMPONESCHI Alessandro	CD38: a regulator of lymphomagenesis in pediatric Burkitt's lymphoma
FB22-71	ORRSJÖ Gustav	Prospectiv monitoring för tidig upptäckt av begynnande återfall av akut myeloisk leukemi
FB22-72	ÄNG E. Ella	Clinical impact of KRAS mutation and associated co-mutations in stage III non-small cell lugn cancer
FB22-73	TAMIRU K. Firaol	Ultrasensitive immunrepertoire sequencing in blood from sarcoma patients
FB22-74	STAFFAS Anna	The role of inflammatory factors for pre-malignant clonal hematopoiesis
FB22-75	BOURGHARDT FAGMAN Johan	Targeting P62-mediated signaling pathways for pancreatic cancer therapeutics
FB22-76	ESCOBAR Mandy	Monitoring disease and treatment efficacy in sarcoma using liquid biopsy analysis
FB22-77	WENNSTRÖM Lovisa	Kan immunstimulerande behandling bota patienter med kronisk myeloisk leukemi?
FB22-78	JOHANSSON ALM Sofie	Förutspår kvarvarande leukemiceller mätt med djupsekvensering återfall vid akut myeloisk leukemi?
FB22-79	OLSSON W. Amanda	Endometriosis induced ovarian cancer, how, why, and who? A study on precancerous events, prediction and assay development for early detection
FB22-80	SAEED R. Borhan	Detection and Characterization of residual Leukemic Cells in Childhood Acute Myeloid Leukemia
FB22-81	KIFFIN Roberta	Examining the role of NOX2 in regulating autophagy in acute myeloid leukemia
FB22-82	ARAUJO Thaís F.	Targeting HER2 positive breast cancer using patient-derived scaffold model and investigation of the immune response
FB22-83	ÖBERG Maria	Macrophage metabolic activation in non-alcoholic steatohepatitis and hepatocellular carcinoma
FB22-84	SOBOLI Anastasia	Prognostisk betydelse av basofiler och mastceller hos barn under behandling för akut myeloisk leukemi med translokation (8;21)
FB22-85	IBRAHIM Raghda	Personalized ctDNA analysis as a marker for treatment response and Relapse of disease in childhood non-hodgkin lymphoma
FB22-86	THOMBARE Ketan S.	Role of m6A in MYCN-amplified neuroblastoma: Mechanisms to therapy
FB22-87	PATEL Angana	Mapping ferroptosis-induced vulnerabilities in KRAS-driven lung adenocarcinoma through genome-wide CRISPR/cas9 screens
FB22-88	HOGG Stephen	Regulatory T cells in human colorectal cancer and inhibition of the anti-tumour immune respons
FB22-89	BORENÄS Marcus	CDK inhibitors in ALK driven neuroblastoma
FB22-90	DZANAN Jozefina	Define the roll of p53 status on keap1 mutant lung cancer sensitivity to glutaminase inhibition
FB22-91	CANSBY Emmelie	Molecular Pathogenesis and new treatment strategies of hepatocellular carcinoma
FB22-92	WERNER R. Elisabeth	Identifiering och validering av nya potentiella biomarkerkörer i bröst - och ovarialcancer
FB22-93	WOJEWODA Karolina	Epidemiology, diagnostic outcomes, and treatment of cutaneous lymphoma
FB22-94	KOMIC Hana	Role of natural killer cells in the control of chronic myeloid leukemia stem cells
FB22-95	ELVBORN Mikael	Optimering av fraktionerad radionuklidterapi av neuroendokrina tumörer
FB22-96	RASSOL Nishte	Effects of co-treatment with 177-Lu-octreate and AIM on gene/protein expression in kidney and GOT1 tumor comparison between administration schedule
FB22-97	GARRELİK Viktor	Identification of molecular factors that governs BSO sensitivity in lugn cancer
FB22-98	ITTNER Ella	Genetic instability and ovarian cancer
FB22-99	NILSSON Malin	Role of redox regulation in chronic myeloid leukemia stem cells

FB22-100	MATEOIU Claudia	Characterization of exome variants in endometriosis and associated ovarian neoplasia
FB22-101	LUNDHOLM Lukas	Tumor characterization and early response assessment of tumor therapy with advanced diffusion MR1
FB22-102	MUSTAFA Dyar	3D-organoids: Patient-derived lung tumour models for drug target validation
FB22-103	YAMAMOTO Io	Mechanism of telomerase-independent telomere maintenance in <i>C. elegans</i>
FB22-104	ROMIANI Arman	A comparative study of ¹⁷⁷ Lu-octreotate and ¹⁷⁷ Lu-octreotide in NB-bearing mice in regard to their: biodistribution, therapeutic effects and influence on apoptosis-related genes
FB22-105	HAGBERG THULIN Malin	Hormonal regulation of sclerotic bone metastases in prostate cancer
FB22-106	LAMBACHER Nils	Identification and characterisation of telomere binding proteins
FB22-107	SCHOULTZ Elin	A new mouse model of sporadic thyroid cancer suitable for in vivo evaluation of targeted drug treatment
FB22-108	SWENSON Hugo	Characterization of novel prognostic and predictive biomarkers in ovarian cancer